27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
Medtronic PLC (NYSE:MDT) is well-positioned for a COVID-19 recovery and has upside to the consensus estimates for fiscal 2022, according to Morgan Stanley.
The Medtronic Analyst: David Lewis upgraded Medtronic from Equal-Weight to Overweight and raised the price target from $120 to $140.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
The Medtronic Thesis: Lagging implantable devices are expected to outperform, with risks being abated by vaccines, better hospital protocols, the availability of personal protective equipment and COVID-19 testing, Lewis said in the upgrade note.
“We see a winning formula for Medtronic, with the company well aligned to our pro-recovery thesis and a material disconnect between Street numbers and the improving post-COVID trajectory,” the analyst said.
"Net, we model 10% FY22/FY19 revenue growth, and Gross and Operating Margins flat in FY22 relative to FY19, which look conservative in light of CFO Karen Parkhill's guidance for a return to normalized underlying growth and Operating Margins in F4Q21."
Morgan Stanley sees reason to be more bullish about Medtronic's pipeline and the turnaround required "to make the company a structural outperformer," Lewis said.
MDT Price Action: Shares of Medtronic were up 2.39% at $114.75 at last check Tuesday.
Photo courtesy of Medtronic.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.